rs7697073 — SCARB2

SCARB2 rs7697073 — The Lysosomal Gatekeeper: When GBA Never Arrives

Inside every neuron, the lysosome is the cell's recycling center — the organelle that breaks down damaged proteins before they can accumulate and aggregate. For the proteins that cause Parkinson's disease and related synucleinopathies, alpha-synuclein¹¹ alpha-synuclein
The small protein that forms Lewy bodies — the pathological hallmark of Parkinson's disease, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), the lysosomal enzyme glucocerebrosidase (GBA)²² glucocerebrosidase (GBA)
Also called beta-glucocerebrosidase or GCase; the enzyme mutated in Gaucher disease whose reduced activity is the single largest genetic risk factor for Parkinson's disease in the general population is the primary degradation catalyst. But GBA has to get into the lysosome first — and that delivery depends on a molecular escort called SCARB2.

SCARB2 (scavenger receptor class B member 2, also known as LIMP-2) is a lysosomal membrane protein that does something no other receptor does: it grabs newly synthesized GBA in the endoplasmic reticulum and ferries it directly to the lysosome through a mannose-6-phosphate-independent trafficking pathway³³ mannose-6-phosphate-independent trafficking pathway
Most lysosomal enzymes are tagged with mannose-6-phosphate and delivered by dedicated receptors; GBA uses SCARB2 as an alternative route that is quantitatively the dominant pathway for GBA delivery. When SCARB2 function is impaired, GBA is secreted into the bloodstream rather than delivered to lysosomes — leaving the cell's recycling machinery without its main enzyme for clearing alpha-synuclein. The intronic variant rs7697073 in SCARB2, identified in the largest genome-wide association study of REM sleep behavior disorder ever conducted⁴⁴ largest genome-wide association study of REM sleep behavior disorder ever conducted
Krohn et al. Genome-wide association study of REM sleep behavior disorder identifies polygenic risk and brain expression effects. Nature Communications, 2022, sits at this critical molecular chokepoint.

The Mechanism

The SCARB2 protein is a 478-amino-acid type III transmembrane glycoprotein embedded in the lysosomal membrane. Its large luminal domain acts as a coiled-coil binding platform that physically docks with GBA in the ER and escort vesicles, then releases the enzyme into the acidic lysosomal lumen when the pH drops — a pH-sensitive binding and release mechanism that ensures GBA is delivered to exactly the right compartment.

Reczek et al. 2007⁵⁵ Reczek et al. 2007
Reczek et al. LIMP-2 is a receptor for lysosomal mannose-6-phosphate- independent targeting of beta-glucocerebrosidase. Cell, 2007 demonstrated that in LIMP-2-deficient cells, the majority of beta-glucocerebrosidase is secreted rather than properly localized to lysosomes, and reconstituting LIMP-2 fully rescues both enzyme delivery and lysosomal distribution. This established SCARB2/LIMP-2 as an indispensable gatekeeper of lysosomal GBA function — not a backup pathway, but the primary one.

Rothaug et al. 2014⁶⁶ Rothaug et al. 2014
Rothaug et al. LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance. PNAS, 2014 extended this to synucleinopathy biology: LIMP-2-deficient mice showed reduced GBA activity in neurons, impaired autophagy-lysosomal function, and toxic alpha-synuclein accumulation in dopaminergic neurons. Remarkably, surviving dopaminergic neurons in human Parkinson's brains showed elevated LIMP-2 levels — a compensatory upregulation that suggests the brain attempts to increase GBA delivery when alpha-synuclein load rises. Overexpressing LIMP-2 accelerated clearance of excess alpha-synuclein in the same model, pointing to SCARB2 expression as a therapeutic lever in synucleinopathy.

rs7697073 is an intronic variant that does not change the SCARB2 protein sequence, but intronic variants in regulatory-active regions can alter splicing efficiency, transcription factor binding site availability, and gene expression levels. The GWAS-identified T allele may act through reduced SCARB2 expression in brainstem or basal ganglia neurons, analogous to how the SNCA 5′ intronic RBD signals operate through altered regulatory RNA expression rather than protein coding changes.

The Evidence

The Krohn 2022 RBD GWAS⁷⁷ Krohn 2022 RBD GWAS
Krohn et al. 2022, Nature Communications enrolled 2,843 isolated RBD cases and 139,636 controls in a multi-cohort meta-analysis — the largest genetic study of RBD ever conducted. SCARB2 emerged as one of five genome-wide significant loci, together with SNCA, GBA, TMEM175, and INPP5F. The SCARB2 locus rs7697073 T allele carries an odds ratio of approximately 1.18 for RBD. A critical finding is that this RBD signal at SCARB2 is genetically independent of the PD-associated SCARB2 variant (rs6812193), meaning the SCARB2 gene harbors at least two distinct signals pointing to different aspects of its biology in different synucleinopathy subtypes.

The SCARB2-RBD connection was first established by Gan-Or et al. 2015⁸⁸ Gan-Or et al. 2015
Gan-Or et al. Parkinson's Disease Genetic Loci in Rapid Eye Movement Sleep Behavior Disorder. J Mol Neurosci, 2015, who showed that the PD-associated rs6812193 T allele (OR=0.67, p=0.004) was also protective against RBD — establishing the SCARB2-synucleinopathy connection before the 2022 GWAS had the statistical power to isolate the independent RBD signal.

Alcalay et al. 2016⁹⁹ Alcalay et al. 2016
Alcalay et al. SCARB2 variants and glucocerebrosidase activity in Parkinson's disease. NPJ Parkinson's Disease, 2016 found that despite SCARB2 rs6812193's association with PD risk (T allele OR=0.71, p=0.004), GBA enzymatic activity was similar across all genotypes — suggesting SCARB2 variants affect synucleinopathy risk through mechanisms beyond simple GBA enzyme level reduction, possibly involving lysosomal membrane organization, alpha-synuclein trafficking, or receptor-mediated signaling independent of GBA delivery.

Practical Actions

The SCARB2-GBA pathway is a target for pharmacological intervention. Ambroxol, a drug originally developed as a mucolytic, acts as a pharmacological chaperone that stabilizes GBA protein and increases its lysosomal delivery — functionally compensating for reduced SCARB2-mediated trafficking in carriers with impaired pathway function. Preclinical studies and early-phase clinical trials have demonstrated that ambroxol increases GBA activity in cerebrospinal fluid and reduces alpha-synuclein levels, making it a candidate intervention specifically for individuals with SCARB2-GBA pathway perturbations.

For T-allele carriers with RBD symptoms, specialist evaluation is the priority — RBD precedes overt synucleinopathy by a decade or more on average, and confirmed RBD opens access to prodromal cohort studies and neuroprotective trials.

Interactions

rs7697073 is genetically distinct from the PD-associated SCARB2 variant rs6812193 and operates in the same pathway as the GBA variants implicated in synucleinopathy risk. The co-identification of SCARB2 and GBA as independent RBD loci in the Krohn 2022 GWAS creates a particularly important interaction: GBA variants reduce glucocerebrosidase enzyme activity directly, while SCARB2 variants may impair GBA lysosomal delivery — both outcomes result in deficient lysosomal GBA and impaired alpha-synuclein clearance. Individuals who carry T alleles at rs7697073 (SCARB2) combined with risk variants at GBA face compounded perturbation of this same pathway from two upstream nodes simultaneously.

rs7697073 was identified in the same GWAS as the SNCA variant rs3756059 (RBD risk), the TMEM175 lysosomal channel variant rs34311866 (PD and RBD risk), and the INPP5F intronic variant rs117896735 (RBD risk). These four loci collectively highlight the autophagy-lysosomal pathway as the central biological substrate of RBD genetic risk — each gene contributing a different node in the pathway from lysosomal enzyme delivery (SCARB2) through enzymatic activity (GBA), lysosomal pH regulation (TMEM175), and membrane trafficking (INPP5F).